A Phase 2a study for STI-3031 for advanced urothelial carcinoma
Latest Information Update: 29 Apr 2021
At a glance
- Drugs Danburstotug (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 29 Apr 2021 New trial record
- 27 Apr 2021 According to a Sorrento Therapeutics media release, the company has filed an IND in the U.S. and received clearance from the FDA to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma.